The Annual Open Enrollment for Medicare prescription drug coverage (Part D) is October 15, 2023 – December 7, 2023 for coverage beginning January 1, 2024. Plans make changes to benefits and costs, and there are also new plans in many areas of the country. Changes to the Part D benefit as a whole may also impact how beneficiaries move through... Read more
Earlier today, the MAPRx Coalition submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the implementation of the Medicare Prescription Payment Plan program set to take effect for Contract Year (CY) 2025 per the Memorandum Maximum Monthly Cap on Cost-Sharing Payments Under Prescription Drug Plans: Draft Part One Guidance on Select Topics, Implementation of Section 1860D-2 of... Read more
Earlier today, the MAPRx Coalition submitted to the Centers for Medicare & Medicaid Services (CMS) comments regarding the implementation of the Medicare Drug Price Negotiation Program (MDPNP) for initial price applicability year 2026.
The Coalition appreciates the opportunity to comment on how Medicare intends to negotiate with
pharmaceutical manufacturers for lower prices on selected high-cost drugs. MAPRx believes... Read more
The Annual Open Enrollment for Medicare prescription drug coverage (Part D) is October 15, 2022 – December 7, 2022 for coverage beginning January 1, 2023. Plans make changes to benefits and costs, and there are also new plans in many areas of the country. Changes to the Part D benefit as a whole may also impact how beneficiaries move through... Read more
A new report commissioned by the MAPRx Coalition examines the growing clinical evidence for coverage of anti-obesity medications (AOMs) approved by the Food and Drug Administration in Medicare Part D.
As the medical community’s understanding of disease states evolves, MAPRx is calling on the Part D program to evolve alongside it to ensure it is providing... Read more
Earlier today, the MAPRx Coalition and 35 member organizations submitted a letter to Senate leadership ahead of their continued consideration of the Inflation Reduction Act of 2022 via the Senate's reconciliation process.
While members of the Coalition have differing views on other components of the expansive package, the Coalition and those signing the letter are in agreement... Read more
We are eager to hear about your experiences with the Medicare prescription drug program. We would like to hear about both good and bad experiences that you have had selecting and signing up for a plan, getting your drugs, and paying for your drugs. The form below will allow you to write your story.
Thank you for taking the time to tell us your story.